Blubuzzard Inc (BZRD)

[The Truth Hurts]

BZRD Change of Control-Overview of Manju Holdings, LLC

Manju Holdings, LLC is a privately held Florida-based limited liability company (LLC) primarily involved in investments and ownership within the pharmaceutical and healthcare sectors. Established as a family-owned entity, it serves as a holding vehicle for strategic acquisitions and operational management of related businesses. The company gained public attention in October 2025 due to its role in a high-profile change-of-control transaction involving a publicly traded entity.

#### Ownership and Leadership
- **Ownership**: Solely owned by Manju Taneja.
- **Management**: Directed by Jugal Taneja, who also holds the position of Chief Executive Officer (CEO) at key affiliated entities.
- **Associated Philanthropy**: Linked to the Taneja Family Foundation, which has made significant donations to healthcare institutions, including funding for medical centers in Florida (e.g., the Taneja Center for Surgery at AdventHealth Tampa). The foundation is reported to manage approximately $30 million in assets, reflecting a commitment to healthcare philanthropy.

#### Key Business Activities and Affiliations
Manju Holdings functions as an investment and operational holding company, with a focus on the pharmaceutical industry:
- **Majority Ownership in Belcher Pharmaceuticals LLC**: A Florida-based company specializing in the development and manufacturing of prescription drug products, including sterile injectables and compounded medications. Belcher operates as a 503B outsourcing facility, compliant with FDA regulations for producing drugs in short supply.
- **Subsidiary: BPI Labs**: A fully owned subsidiary of Belcher Pharmaceuticals, BPI Labs is an FDA-registered manufacturer known for producing compounded versions of GLP-1 receptor agonists (e.g., semaglutide and tirzepatide) during the 2022–2025 shortages. BPI has partnerships with telehealth providers like Hims & Hers and has been involved in legal challenges against patent holders (e.g., Eli Lilly) to extend compounding access. As of November 2025, BPI has resumed limited production of personalized GLP-1 formulations under FDA's post-shortage guidelines.

The holding structure positions Manju Holdings at the apex, enabling consolidated control over pharmaceutical operations, R&D, and distribution.

#### Recent Developments: Acquisition and Merger Speculation
On or about October 16, 2025, Manju Holdings acquired a controlling (majority) interest in High Velocity Ventures, Inc. (OTC: BZRD, formerly Blubuzzard, Inc.), a Tampa, Florida-based shell company. This transaction marked a significant change of control, announced publicly on October 27, 2025.

- **Strategic Intent**: The acquisition is widely interpreted as a reverse merger vehicle to take Belcher Pharmaceuticals (and by extension, BPI Labs) public. This would provide access to capital markets for expansion amid the evolving GLP-1 market, where compounded drugs offer cost-effective alternatives to branded products from Novo Nordisk and Eli Lilly.
- **Market Context**: With the FDA resolving national GLP-1 shortages in early 2025 (semaglutide on February 21, tirzepatide on October 14, 2024), compounding facilities like BPI face regulatory scrutiny but opportunities in "personalized" formulations. A public listing via BZRD could fund innovation, such as vitamin-enhanced GLP-1s or new sterile injectables.
- **Speculation on X (formerly Twitter)**: Recent discussions highlight the Taneja family's interconnected entities, with users noting the foundation's assets and BPI's role in tirzepatide compounding lawsuits. Enthusiasm centers on potential synergies with telehealth ($HIMS) and broader market growth.

#### Implications and Outlook
- **For Investors**: The BZRD ticker has seen speculative interest post-announcement, with potential for a formal merger filing soon. However, OTC markets carry risks, including volatility and disclosure requirements.
- **For Healthcare**: Strengthens access to affordable compounded medications, especially as branded GLP-1 prices remain high ($1,000+/month). BPI's production restart in November 2025 aligns with FDA's "green list" for imported ingredients, targeting localized shortages.
- **Regulatory Note**: As a 503B facility, operations emphasize safety (e.g., ISO-grade robotic production), but compounded drugs lack full FDA approval and may involve risks like dosing variability.

For the most current details, such as SEC filings or merger updates, monitor OTC Markets for BZRD or contact Belcher Pharmaceuticals directly (e.g., via belcherpharma.com). If this query relates to a specific aspect (e.g., investments or philanthropy), provide more context for deeper analysis!